Shardan M. Radmanesh
Radiology at Broadway, Lexington, KY
License number
Kentucky 44326
Issued Date
Jun 16, 2011
Expiration Date
Feb 28, 2018
Category
Diagnostic Radiology
Type
Hospital Based
Address
Address
1218 S Broadway STE 310, Lexington, KY 40504
Education
University of Kentucky College of Medicine, Lexington, 2006
Phone
(859) 219-0542 (Work)
Personal information
See more information about Shardan M. Radmanesh at radaris.comName
Address
Phone
3773 Branham Park, Lexington, KY 40515
Lexington, KY
3729 Winthrop Dr, Lexington, KY 40514
107 Wildcat Dr, Somerset, KY 42501
189 Holmes Hall, Lexington, KY 40503
Organization information
See more information about Shardan M. Radmanesh at bizstanding.comShardan M Radmanesh MD
1218 S Broadway, Lexington, KY 40504
Categories:
Radiology Physicians & Surgeons
Phone:
(859) 219-0542 (Phone)
Professional information
See more information about Shardan M. Radmanesh at trustoria.com
Shardan Marc Radmanesh, Lexington KY
Shardan Marc Radmanesh, Lexington KY
Specialties:
Radiologist
Address:
1218 S Broadway, Lexington, KY 40504
Education:
Doctor of Medicine*
Board certifications:
American Board of Radiology Certification in Diagnostic Radiology (Radiology)*
Tyrosine Kinase Inhibitors As An Adjunctive Therapy To Botulinum Toxin Treatment
Tyrosine Kinase Inhibitors As An Adjunctive Therapy To Botulinum Toxin Treatment
US Patent:
2004022, Nov 18, 2004
Filed:
Feb 21, 2004
Appl. No.:
10/784028
Inventors:
Philip Hallinger Bonner - Lexington KY, US
Roberts Baker - Lexington KY, US
Shardan Marc Radmanesh - Lexington KY, US
William Wallace Richardson - Lexington KY, US
Roberts Baker - Lexington KY, US
Shardan Marc Radmanesh - Lexington KY, US
William Wallace Richardson - Lexington KY, US
International Classification:
A61K039/00, A61K039/38
US Classification:
424/184100
Abstract:
The present invention is directed to methods for extending the duration of the therapeutic effect of a botulinum toxin in an animal. The methods involve the administration of a botulinum toxin, preferably botulinum toxin A, to treat a condition or disorder, and administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to extend the duration of the therapeutic effect of a botulinum toxin. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
Inhibition Of Muscle Regeneration Following Myectomy
Inhibition Of Muscle Regeneration Following Myectomy
US Patent:
2003018, Sep 25, 2003
Filed:
Mar 19, 2003
Appl. No.:
10/392649
Inventors:
Robert Baker - Lexington KY, US
Philip Bonner - Lexington KY, US
Shardan Radmanesh - Lexington KY, US
Philip Bonner - Lexington KY, US
Shardan Radmanesh - Lexington KY, US
International Classification:
A61K031/382, A61K031/353
US Classification:
514/432000, 514/456000
Abstract:
A method of inhibiting skeletal muscle regeneration following myectomy is disclosed. The method involves administering a tyrosine kinase inhibitor to an animal following myectomy of at least one muscle. Genistein is a preferred tyrosine kinase inhibitor under the present invention.